Last $11.52 USD
Change Today -0.08 / -0.69%
Volume 721.0K
MNTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Open
$11.62
Previous Close
$11.60
Day High
$11.72
Day Low
$11.26
52 Week High
01/9/14 - $19.90
52 Week Low
05/6/14 - $9.85
Market Cap
608.4M
Average Volume 10 Days
338.7K
EPS TTM
$-2.13
Shares Outstanding
52.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MOMENTA PHARMACEUTICALS INC (MNTA)

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923 and M834, which are biosimilars for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 1/2 clinical study, which binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor progression, metastasis, and angiogenesis; and the sialylation technology that is a discovery program of a mixture of human immunoglobulin G antibodies for the treatment of inflammatory diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

269 Employees
Last Reported Date: 02/28/14
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $621.0K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $387.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $362.5K
President of Biosimilars Business
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $395.7K
Compensation as of Fiscal Year 2013.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA

Momenta Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE(R) (glatiramer acetate injection, 40 mg/mL), submitted by Sandoz Inc., Momenta's development and commercialization partner for this product candidate.

Momenta Pharmaceuticals Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Financial Guidance for the Second Half of 2014

Momenta Pharmaceuticals Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, total collaboration revenue was $10,950,000 against $4,361,000 a year ago. Operating loss was $26,358,000 against $29,149,000 a year ago. Net loss was $26,156,000 against $28,848,000 a year ago. Basic and diluted net loss per share was $0.51 against $0.57 a year ago. For the six months, total collaboration revenue was $21,735,000 against $11,964,000 a year ago. Operating loss was $53,982,000 against $53,595,000 a year ago. Net loss was $53,518,000 against $52,965,000 a year ago. Basic and diluted net loss per share was $1.04 against $1.04 a year ago. The company updated its financial guidance for the second half of 2014. The company expects total operating expenses, excluding stock-based compensation and net of collaborative revenues, to average $28 to $30 million per quarter. The company is projecting that its net cash usage, excluding revenue from the potential launch of M356, will average approximately $26 million per quarter. Cash burn for the fourth quarter of 2014 is expected to be partially offset by $19 million from milestone payments earned under the Baxter collaboration, although all or a portion of these milestone payments could be received in the first quarter of 2015.

Momenta Pharmaceuticals Inc. to Report Q2, 2014 Results on Jul 31, 2014

Momenta Pharmaceuticals Inc. announced that they will report Q2, 2014 results at 9:00 AM, Eastern Standard Time on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $11.52 USD -0.08

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eagle Pharmaceuticals Inc/DE $12.26 USD -0.27
Natco Pharma Ltd 1,525 INR +33.55
OraSure Technologies Inc $7.73 USD +0.10
Pernix Therapeutics Holdings Inc $7.47 USD -0.10
Sucampo Pharmaceuticals Inc $6.71 USD +0.08
View Industry Companies
 

Industry Analysis

MNTA

Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit www.momentapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.